Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Nancy E Martin"'
Publikováno v:
Kidney International Reports, Vol 4, Iss 9, Pp 1235-1247 (2019)
Introduction: This double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney dise
Externí odkaz:
https://doaj.org/article/445bc210f8f64851b7ff9049a1a16833
Autor:
Jay B. Wish, Marcelo G. Rocha, Nancy E. Martin, Christian Russel D. Reyes, Steven Fishbane, Mark T. Smith, George Nassar
Publikováno v:
Kidney Medicine, Vol 1, Iss 5, Pp 271-280 (2019)
Rationale & Objective: Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa. We compare the safety of epoetin alfa-epbx versus epoetin alfa based on a pooled analysis of findings from 2 randomized, double-blind, comparative clinic
Externí odkaz:
https://doaj.org/article/70749e3d84df4eb6b74e165829bc5d05
Publikováno v:
Kidney International Reports, Vol 4, Iss 9, Pp 1235-1247 (2019)
Kidney International Reports
Kidney International Reports
Introduction: This double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney dise
Autor:
Marcelo G. Rocha, Jay B. Wish, Mark T. Smith, Steven Fishbane, Nancy E. Martin, Christian Russel D. Reyes, George M. Nassar
Publikováno v:
Kidney Medicine, Vol 1, Iss 5, Pp 271-280 (2019)
Kidney Medicine
Kidney Medicine
Rationale & Objective Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa. We compare the safety of epoetin alfa-epbx versus epoetin alfa based on a pooled analysis of findings from 2 randomized, double-blind, comparative clinica
Publikováno v:
Clinical Journal of the American Society of Nephrology. 13:1204-1214
Background and objectives This study was conducted to compare the safety and efficacy of intravenous epoetin alfa-epbx, an epoetin alfa biosimilar, to epoetin alfa in patients on hemodialysis with ESKD and anemia. Design, setting, participants, & mea
Publikováno v:
Clinical Therapeutics. 38:1778-1788
Purpose The purpose of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of single 100 U/kg subcutaneous doses of Epoetin Hospira and Epogen in healthy male subjects as part of an overall program to demonstrate
Autor:
Roger Vogel, Richard A. Lewis, Dennis Swearingen, Nancy E. Martin, Scott Rasmussen, Neha Sheth, Gary Hantsbarger, Gary D. Novack
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 29:674-680
This study assessed the effect of mirabegron on ocular safety in healthy volunteers.This was an 8-week, randomized, double-masked, placebo-controlled study.Consenting adults aged ≥18 years with a normal intraocular pressure (IOP, ≥10 to ≤21 mmH
Autor:
Dennis J Stalker, Susan Reid, Seema Kumbhat, Nancy E. Martin, Jeffrey Zhang, Atulkumar Ramaiya
Publikováno v:
Clinical therapeutics. 38(5)
Purpose The purpose of this study was to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) equivalences of multiple doses of the proposed biosimilar Epoetin Hospira to the reference product Epogen ⁎ ⁎Epogen ® (epoetin alfa; Amgen, Thous
Publikováno v:
The Journal of Clinical Pharmacology. 44:1379-1384
M100240 is a thioester of MDL 100,173, a dual angiotensin-converting enzyme (ACE)/neutral endopeptidase (NEP) inhibitor. Clinical studies have shown that M100240 is capable of decreasing ACE activity and angiotensin II concentrations while increasing
Autor:
Barbara J. Brennan, Nancy E. Martin
Publikováno v:
Journal of the American Pharmacists Association. 44:604-611
Objective To review the pharmacology, safety, and efficacy data, as well as therapeutic use of eplerenone (Inspra—Pfizer) for management of cardiovascular and renal disease. Data Sources A Medline search (January 1980–July 2003) was performed usi